Why the FDA hearing on Vanda Pharmaceuticals’ HETLIOZ could reshape drug approval challenges
FDA grants rare hearing to review Vanda Pharmaceuticals’ HETLIOZ jet lag application. Discover what this regulatory fight could mean for circadian medicine.
Biofrontera targets U.S. label expansion for Ameluz in trunk and extremities
Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.